title: Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.
abstract: Effectiveness of nanomedicines in cancer therapy is limited in part by inadequate delivery and transport in tumor interstitium. This article reviews the experimental approaches to improve nanomedicine delivery and transport in solid tumors. These approaches include tumor vasculature normalization, interstitial fluid pressure modulation, enzymatic extracellular matrix degradation, and apoptosis-inducing tumor priming technology. We advocate the latter approach due to its ease and practicality (accomplished with standard-of-care chemotherapy, such as paclitaxel) and tumor selectivity. Examples of applying tumor priming to deliver nanomedicines and to design drug/RNAi-loaded carriers are discussed.
authors.affiliation: Optimum Therapeutics LLC, The Ohio State University Science Tech Village, Columbus, OH 43212, USA.
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Ze
authors.initials: Z
authors.lastname: Lu
authors.forename: Yue
authors.initials: Y
authors.lastname: Gao
authors.forename: M Guillaume
authors.initials: MG
authors.lastname: Wientjes
authors.forename: Jessie L-S
authors.initials: JL
authors.lastname: Au
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel
references.citation: Pharm Res. 1998 Jan;15(1):122-7
references.pmid: 9487558
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5287-97
references.pmid: 19738110
references.citation: Cancer Res. 1999 Aug 1;59(15):3776-82
references.pmid: 10446995
references.citation: Cancer Chemother Pharmacol. 1998;42(3):177-82
references.pmid: 9685052
references.citation: J Pharmacol Exp Ther. 2000 Jun;293(3):761-70
references.pmid: 10869374
references.citation: Nat Med. 2003 Jun;9(6):796-800
references.pmid: 12754503
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3942-50
references.pmid: 17606728
references.citation: Clin Cancer Res. 2010 May 15;16(10):2760-8
references.pmid: 20460479
references.citation: AAPS PharmSci. 1999;1(3):E8
references.pmid: 11741204
references.citation: Cancer Res. 1998 Jul 1;58(13):2777-83
references.pmid: 9661891
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9
references.pmid: 19246386
references.citation: Science. 2010 May 21;328(5981):1031-5
references.pmid: 20378772
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1317-24
references.pmid: 16489089
references.citation: Hum Gene Ther. 2005 Apr;16(4):435-44
references.pmid: 15871675
references.citation: Science. 2009 Jun 12;324(5933):1400-1
references.pmid: 19520948
references.citation: Nanomedicine (Lond). 2010 Jun;5(4):523-8
references.pmid: 20528447
references.citation: Mol Pharm. 2008 Jul-Aug;5(4):505-15
references.pmid: 18672949
references.citation: J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):239-42
references.pmid: 9039176
references.citation: Clin Cancer Res. 2002 May;8(5):1038-44
references.pmid: 12006516
references.citation: J Pharmacol Exp Ther. 2001 Mar;296(3):1035-42
references.pmid: 11181938
references.citation: Cancer Cell. 2004 Dec;6(6):553-63
references.pmid: 15607960
references.citation: Cancer Chemother Pharmacol. 1997;41(1):69-74
references.pmid: 9443616
references.citation: Science. 2009 Jun 12;324(5933):1457-61
references.pmid: 19460966
references.citation: J Biomed Nanotechnol. 2009 Apr;5(2):151-61
references.pmid: 20055093
references.citation: Int J Pharm. 2004 Feb 11;270(1-2):93-107
references.pmid: 14726126
references.citation: Cancer Res. 1995 Sep 1;55(17):3752-6
references.pmid: 7641188
references.citation: Gene Ther. 2006 Aug;13(16):1222-34
references.pmid: 16625243
references.citation: Cancer Chemother Pharmacol. 1995;35(4):297-303
references.pmid: 7828272
references.citation: J Pharmacol Exp Ther. 2008 Dec;327(3):673-82
references.pmid: 18780831
references.citation: Invest New Drugs. 2001 May;19(2):113-23
references.pmid: 11392446
references.citation: AAPS J. 2010 Jun;12(2):223-32
references.pmid: 20198462
references.citation: J Urol. 1989 Mar;141(3):529-30
references.pmid: 2493098
references.citation: Semin Oncol. 2000 Jun;27(3):347-61
references.pmid: 10864222
references.citation: J Gene Med. 2010 Jun;12(6):516-27
references.pmid: 20527044
references.citation: Pharm Res. 2003 Sep;20(9):1337-50
references.pmid: 14567626
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: Nat Rev Drug Discov. 2009 Feb;8(2):129-38
references.pmid: 19180106
references.citation: Jpn J Cancer Res. 1988 Jul;79(7):874-9
references.pmid: 2971639
references.citation: Clin Cancer Res. 2000 Dec;6(12):4823-30
references.pmid: 11156241
references.citation: Cancer Sci. 2009 Dec;100(12):2426-30
references.pmid: 19793083
references.citation: Cancer Surv. 1993;17:283-304
references.pmid: 7907949
references.citation: J Pharmacol Exp Ther. 2007 Jul;322(1):80-8
references.pmid: 17420296
references.citation: Br J Cancer. 2005 Jul 11;93(1):81-8
references.pmid: 15942637
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1798-808
references.pmid: 20515941
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer Res. 2004 Jul 15;64(14):4768-73
references.pmid: 15256445
references.citation: Jpn J Cancer Res. 1994 Apr;85(4):331-4
references.pmid: 7515384
references.citation: Am J Pathol. 2006 Oct;169(4):1415-26
references.pmid: 17003496
references.citation: Int J Cancer. 1997 Jan 17;70(2):214-20
references.pmid: 9009163
references.citation: J Control Release. 2008 Apr 7;127(1):41-9
references.pmid: 18234388
references.citation: J Natl Cancer Inst. 1981 Sep;67(3):663-9
references.pmid: 6944536
references.citation: Cancer Res. 1998 May 15;58(10):2141-8
references.pmid: 9605758
references.citation: Cancer Cell. 2004 Dec;6(6):529-31
references.pmid: 15607955
references.citation: AAPS J. 2010 Dec;12(4):492-503
references.pmid: 20544328
references.citation: Mol Pharm. 2011 Jun 6;8(3):833-40
references.pmid: 21417439
references.citation: Mol Cancer Res. 2006 Feb;4(2):61-70
references.pmid: 16513837
references.citation: J Pharm Sci. 1978 May;67(5):696-700
references.pmid: 641813
references.citation: Am J Pathol. 1996 May;148(5):1345-50
references.pmid: 8623905
references.citation: Cancer Res. 2008 May 15;68(10):3795-802
references.pmid: 18483263
references.citation: Clin Cancer Res. 2001 Sep;7(9):2862-9
references.pmid: 11555604
references.citation: Cancer Res. 1996 May 1;56(9):2086-93
references.pmid: 8616855
references.citation: Breast Cancer Res. 2009;11(4):R43
references.pmid: 19575785
references.citation: Future Oncol. 2010 Oct;6(10):1625-41
references.pmid: 21062160
references.citation: Pharm Res. 2007 Sep;24(9):1691-701
references.pmid: 17447121
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1906-12
references.pmid: 16551876
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: J Pharmacol Exp Ther. 1999 Aug;290(2):871-80
references.pmid: 10411604
references.citation: J Clin Oncol. 2006 Feb 1;24(4):688-94
references.pmid: 16446342
references.citation: Int J Nanomedicine. 2007;2(2):265-74
references.pmid: 17722554
references.citation: Cancer Res. 2000 Aug 15;60(16):4440-5
references.pmid: 10969790
references.citation: Cancer Res. 2006 Mar 1;66(5):2509-13
references.pmid: 16510565
references.citation: Nat Rev Cancer. 2010 Jan;10(1):9-22
references.pmid: 20029421
references.citation: N Engl J Med. 1995 Apr 13;332(15):1004-14
references.pmid: 7885406
references.citation: Jpn J Clin Oncol. 2009 Nov;39(11):756-66
references.pmid: 19596662
references.citation: Clin Cancer Res. 1998 Feb;4(2):277-82
references.pmid: 9516911
references.citation: Br Med J. 1972 Mar 4;1(5800):597-601
references.pmid: 4111169
references.citation: Clin Cancer Res. 2006 Nov 15;12(22):6748-57
references.pmid: 17121895
references.citation: Nat Rev Cancer. 2005 Mar;5(3):161-71
references.pmid: 15738981
references.citation: AAPS PharmSci. 2001;3(2):E15
references.pmid: 11741266
references.citation: N Engl J Med. 2010 Dec 16;363(25):2434-43
references.pmid: 21158659
references.citation: Cancer Res. 1989 Aug 15;49(16):4373-84
references.pmid: 2545340
references.citation: Cancer Cell. 2009 Dec 8;16(6):510-20
references.pmid: 19962669
references.citation: J Control Release. 2001 Jul 6;74(1-3):31-46
references.pmid: 11489481
references.citation: Drugs. 1994 Nov;48(5):794-847
references.pmid: 7530632
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62
references.pmid: 19805273
references.citation: FASEB J. 2005 Mar;19(3):311-30
references.pmid: 15746175
references.citation: Mol Pharm. 2008 Jul-Aug;5(4):496-504
references.pmid: 18611037
references.citation: Transl Oncol. 2009 May;2(2):59-64
references.pmid: 19412420
references.citation: FASEB J. 2008 Jan;22(1):276-84
references.pmid: 17761521
references.citation: Cancer Res. 1991 Jan 1;51(1):265-73
references.pmid: 1988088
references.citation: Cancer Res. 2000 May 1;60(9):2497-503
references.pmid: 10811131
references.citation: Cancer Res. 2007 Nov 15;67(22):10664-8
references.pmid: 18006807
references.citation: J Neurooncol. 2009 Jun;93(2):285-6
references.pmid: 19048187